BER Inc

BER Inc has most recently have been working in the development of large molecule and cell based immuno-oncology therapeutics. This includes development of novel in-vitro and ex vivo assays for assessing efficacy of new candidates. This includes the development of new competent and immunocompromised mouse models for a number of modalities including large molecule and for allogeneic CAR-T therapeutics.